Silence Therapeutics plc
Silence Therapeutics develops siRNA therapies using its mRNAi GOLD platform to target genes causing disease.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
November 2026
October 2026
August 2026
July 2026
Silence Therapeutics develops siRNA therapies using its mRNAi GOLD platform to target genes causing disease.
November 2026
October 2026
August 2026
July 2026